Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...